遗传多态性对伴随性疾病的差异性影响在代谢功能障碍相关的稳态性肝病中
Yuya Seko1, Kanji Yamaguchi1, Toshihide Shima2
1Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyou-ku, Kyoto, Japan.
概括
PNPLA3和TM6SF2的遗传变异增加了与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的肝脏相关事件风险. 这种遗传风险得分有助于LRE预测,特别是在日本的年轻,非肥胖,非糖尿病个体中.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 遗传学 遗传学是一种遗传学.
- 代谢疾病 代谢疾病
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 具有与肝脏相关事件 (LREs) 的显著风险.
- 特定的基因变异,包括PNPLA3 rs738409,TM6SF2 rs58542926和HSD17B13 rs72613567,已与MASLD患者的LRE风险增加有关.
- 调查这些变体的综合影响对于完善风险分层至关重要.
研究的目的:
- 评估PNPLA3,TM6SF2和HSD17B13基因变异对活检证明MASLD的患者肝脏相关事件 (LREs) 风险的综合影响.
- 开发和验证基因风险评分,用于预测该人群中的LREs.
- 确定可能从遗传风险评估中获益最多的MASLD患者的子组.
主要方法:
- 一项纵向的多中心队列研究,涉及1178名活检证明MASLD的患者.
- 基因风险评分的计算基于PNPLA3,TM6SF2和HSD17B13变体的综合影响.
- 多变量分析以评估遗传风险得分和LRE发展之间的关联,考虑肥胖和糖尿病等临床因素.
主要成果:
- 基因纤维化得分较高的患者 (2-5) 与得分为0-1的患者相比,LREs的几率显著增加.
- PNPLA3和TM6SF2变种,但不是HSD17B13,与LRE发展独立相关.
- 一个基因高风险组显示,LREs的危险增加了1.91倍,特别明显在年轻,非肥胖和非糖尿病患者中.
结论:
- PNPLA3,TM6SF2和HSD17B13变体的组合是预测日本MASLD患者的LREs的一个有价值的工具.
- 开发的遗传风险评分提高了LRE风险评估,特别是在没有代谢风险因素的个体或年轻患者中.
- 这种遗传方法为MASLD的个性化风险管理提供了一个有希望的策略.
相关概念视频
Overview of Lipid Metabolism
1.5K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.5K
Factors Affecting Drug Biotransformation: Biological
147
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
147
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Overview of Carbohydrate Metabolism
981
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
981
Diseases of the Liver and Gallbladder
533
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
533
Inborn Errors of Metabolism
157
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
157


